Phase III studies show bimekizumab meets endpoints in moderate to severe plaque psoriasis

5 February 2021

Belgium’s largest drugmaker UCB (Euronext Brussels: UCB) today announced that The Lancet has published positive results from BE VIVID and BE READY, two Phase III studies evaluating the efficacy and safety profile of bimekizumab, its investigational interleukin (IL)-17A and IL-17F inhibitor, in the treatment of adults with moderate to severe plaque psoriasis.

“The simultaneous publication of data from two bimekizumab Phase III studies in one of medicine’s most authoritative titles, The Lancet, speaks to the significance of these psoriasis studies. We’re grateful to the patients and investigators who participated in the studies, and we’re committed to working with the regulatory agencies to bring bimekizumab to patients,” said Emmanuel Caeymaex, executive vice president, Immunology Solutions and head of US, UCB.

Achieved superior levels of skin clearance

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK